Quarterly Results, Collaborations and Product Launches - Research Report on Onyx Pharmaceuticals, Express Scripts, NPS Pharmaceuticals, Salix Pharmaceuticals, and MannKind Corporation

LONDON, August 14, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX), Express Scripts Holding Company (NASDAQ: ESRX), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), and MannKind Corporation (NASDAQ: MNKD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Onyx Pharmaceuticals, Inc. Research Report

On August 8, 2013, Onyx Pharmaceuticals, Inc. (Onyx Pharmaceuticals) announced that it is collaborating with Idis Limited to initiate a Managed Access Program for carfilzomib in some European countries for the treatment of patients with multiple myeloma, who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of the completion of the last therapy. Managed Access Programs enables biopharmaceutical companies to allow eligible patients ethical access to medicines for unmet medical needs. Pablo J. Cagnoni, M.D., Executive Vice President, Global Research & Development and Technical Operations at Onyx Pharmaceuticals, said, "Idis is the recognized leader in Managed Access Programs, making them an ideal partner to oversee this important initiative on behalf of Onyx." The Full Research Report on Onyx Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-12/ONXX]

Express Scripts Holding Company Research Report

On August 1, 2013, Express Scripts Holding Company (Express Scripts) and Walgreens (Walgreens) announced the launch of Smart90 Walgreens, a new program for Express Scripts clients interested in 90-day prescription drug programs that result in lower costs and improve health outcomes for patients with chronic disease who require long-term treatment. According to Express Scripts, with Smart90 Walgreens, plan sponsors that wish to include Walgreens as part of the Smart90 program for their pharmacy benefit will provide their members who have chronic conditions the choice to receive 90-day supplies of maintenance medications through home delivery from Express Scripts or directly at a Walgreens retail pharmacy for the same copayment. Glen Stettin, M.D., Senior Vice President of Research and New Solutions at Express Scripts, said, "Members will be able to continue to receive the safety, convenience, cost savings and care offered from Express Scripts home delivery pharmacies." The Full Research Report on Express Scripts Holding Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-12/ESRX]

NPS Pharmaceuticals, Inc. Research Report

On August 8, 2013, NPS Pharmaceuticals, Inc. (NPS Pharmaceuticals) reported its Q2 2013 financial results. The Company's total revenues declined 31.8% YoY to $36.5 million during the quarter. Net loss was $12.4 million, or $0.13 per diluted share, in Q2 2013, compared to net income of $7.4 million, or $0.08 per diluted share, in Q2 2012. Net product sales for Gattex, launched in Q1 2013 totaled $4.8 million in Q2 2013. Commenting on the results, Francois Nader, MD, President and Chief Executive Officer of NPS Pharmaceuticals, said, "Our commitment to flawless execution has yielded solid second quarter results including Gattex sales that exceeded our own expectations. We are particularly gratified to have already brought this life-changing treatment to 141 Short Bowel Syndrome patients and I am pleased to report that we are increasing our guidance to 275 to 325 patients on therapy by the end of the year." The Full Research Report on NPS Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-12/NPSP]

Salix Pharmaceuticals, Ltd. Research Report

On August 8, 2013, Salix Pharmaceuticals, Ltd. (Salix Pharmaceuticals) reported its Q2 2013 financial results and other business updates.The Company's net product revenue grew 30.1% YoY to $235.4 million for the quarter. Net income was $21.0 million, or $0.32 per diluted share, in Q2 2013, compared to net income of $20.1 million, or $0.32 per diluted share, in Q2 2012. Commenting on the results, Adam Derbyshire, Executive Vice President and Chief Financial Officer, said, "During the quarter our XIFAXAN 550 mg prescription business demonstrated impressive growth of 26% compared to the second quarter of 2012. APRISO also demonstrated strong prescription year-over-year growth of 45% for the second quarter of 2013 compared to the second quarter of 2012. RELISTOR prescriptions increased 48% year-over-year for the second quarter of 2013 compared to the second quarter of 2012." The Full Research Report on Salix Pharmaceuticals, Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-12/SLXP]

MannKind Corporation Research Report

On August 9, 2013, MannKind Corporation (MannKind) reported its Q2 2013 financial results. The Company's total operating expenses decreased 5.6% YoY to $41.6 million during the quarter. Research and development (R&D) expenses increased 1.6% YoY to $27.1 million in Q2 2013, primarily due to an increase in non-cash stock compensation expense partially offset by a decrease in clinical trial related expenses. Net loss applicable to common stockholders was $46.1 million, or $0.16 per diluted share, in Q2 2013, compared to net loss of $36.6 million, or $0.23 per diluted share, in Q2 2012. Cash and cash equivalents were $28.5 million as of June 30, 2013, compared to $61.8 million as of December 31, 2012, with $125.4 million remaining available for future borrowings under the loan agreement with Mann Group through September 30, 2013. The Full Research Report on MannKind Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-12/MNKD]

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Investors' Reports